{
    "title": "112_s1882",
    "content": "The Act is known as the \"Fair And Immediate Release of Generic Drugs Act\" or the \"FAIR Generics Act.\" It includes amendments regarding the 180-day exclusivity period for first applicants. The \"Fair And Immediate Release of Generic Drugs Act\" or the \"FAIR Generics Act\" includes amendments to the Federal Food, Drug, and Cosmetic Act regarding the definition of a \"first applicant\" for drug approval. The \"FAIR Generics Act\" amends the Federal Food, Drug, and Cosmetic Act by defining requirements for drug approval, including certifications and agreements for first applicants. The \"FAIR Generics Act\" outlines requirements for drug approval, including certifications and agreements for first applicants regarding patent infringement actions. The \"FAIR Generics Act\" outlines requirements for drug approval, including certifications and agreements for first applicants regarding patent infringement actions. If an applicant has obtained a court decision that the patent is invalid or not infringed, they may delay commercial marketing of the drug. The \"FAIR Generics Act\" outlines requirements for drug approval, including certifications and agreements for first applicants regarding patent infringement actions. An amendment specifies the definition of the first applicant in a section of the Federal Food, Drug, and Cosmetic Act. The amendment only applies to applications filed under specific provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. SEC. 3. 180-DAY EXCLUSIVITY PERIOD AMENDMENTS REGARDING AGREEMENTS TO DEFER COMMERCIAL MARKETING. Amendments to the Federal Food, Drug, and Cosmetic Act regarding limitations on agreements to defer commercial marketing dates. An agreement between a first applicant and the holder of the application for the listed drug or patents to defer approval or commercial marketing date. The applicant agrees not to seek early approval or market the drug before a certain date to qualify for the 180-day exclusivity period. The subclause involves an agreement where an applicant agrees not to seek approval or market their drug before a specified date to qualify for the 180-day exclusivity period. The agreement limits the acceleration of approval for an applicant's drug, allowing them to seek approval or begin marketing on the earliest specified date in the agreement. The agreement sets limits on the approval and marketing timeline for a drug applicant, specifying the earliest date they can seek approval or begin marketing. The holder of an abbreviated application must submit a notification to the FDA including the text or detailed description of any agreement related to approval and marketing timelines for a drug applicant. The holder of an abbreviated application must submit a notification to the FDA regarding any related agreements within 10 business days of execution. The information provided is confidential and exempt from disclosure, except in certain legal proceedings. The FDA must be notified of any related agreements by the holder of an abbreviated application within 10 business days. The information is confidential and exempt from disclosure, except in specific legal proceedings. Amendments are made to sections of the Federal Food, Drug, and Cosmetic Act regarding prohibited acts and infringement of patents. Amendments to the Federal Food, Drug, and Cosmetic Act specify limitations on accelerating deferred commercial marketing dates for certain applications and agreements. FDA notification is required for related agreements within 10 business days, with confidentiality provisions. The amendments to the Federal Food, Drug, and Cosmetic Act require FDA notification for agreements related to deferred commercial marketing dates, with limitations on acceleration, applicable only to agreements executed after the enactment of the Act."
}